Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multicenter, Double-Blind, Flexibly-dosed, Efficacy and Safety Study of Escitalopram in the Treatment of Children and Adolescents With Generalized Anxiety Disorder

NCT03924323 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT03924323
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03924323 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multicenter, Double-Blind, Flexibly-dosed, Efficacy and Safety Study of Escitalopram in the Treatment of Children and Adolescents With Generalized Anxiety Disorder
Lead sponsor
AbbVie
Phase
Phase 4
Overall status
Completed
Start date
May 30, 2019
Completion date
September 20, 2021
Enrollment
273 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

anxiety disorders,generalized anxiety disorder